PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 10:47 AM ET

Sponsor Check › Person

JD
No photo found yet (own website and image search run after this page is viewed)

Jay Lichter, Ph.D.

Named as an officer, director or promoter on SEC Form D filings · CA · Apr 23, 2010 → Jul 1, 2025

6deals (issuers)
$199.6Mreported sold
87investors
13Form D filings
2010–2025years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:17 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Jay Lichter, Ph.D. is listed as an executive officer and director on 13 SEC Form D filings by 6 issuers between Apr 2010 and Jul 2025. Largest by amount reported sold: Janux Therapeutics, Inc. (La Jolla, CA — biotechnology — 2020–2021; $125M reported sold to 22 investors), ARATANA THERAPEUTICS, INC. (Kansas City, KS — pharmaceuticals — 2013; $29.8M reported sold to 17 investors), Otonomy, Inc. (San Diego, CA — biotechnology — 2010; $24.2M reported sold to 13 investors), Arialys Therapeutics, Inc. (La Jolla, CA — biotechnology — 2022–2025; $14.8M reported sold to 7 investors), Nerio Therapeutics, Inc. (La Jolla, CA — biotechnology — 2020–2021; $3.5M reported sold to 5 investors) and 1 more (all listed below).

What this means A repeat sponsor — 6 separate companies raised money with this person listed as executive officer and director, over about 15 years. Across those companies the filings report $199.6M sold in total.

Listed alongside Tighe Reardon (6 shared filings), Douglas Downs (5 shared filings), Stefan Heller (5 shared filings), David Campbell, Ph.D. (3 shared filings), Kevin Kinsella (3 shared filings) and 28 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jay. Each name links to their own page.

The issuers belong to 2 sponsor groups: Avalon (15 issuers, $705.3M reported sold, 2010–2025) and Zacharon (2 issuers, $24.2M reported sold, 2010–2012).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — none found.

What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 13 public filings for Jay Lichter, Ph.D. and found 8 differences, 1 worth asking the sponsor about: Jay Lichter, Ph.D. is no longer listed on the Jun 2, 2011 amendment; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Jay Lichter, Ph.D. has not run yet — it is #33,907 of 60,995 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 708 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:17 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Jay Lichter, Ph.D...

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:17 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

8 differences found between the filings for Jay Lichter, Ph.D. — 1 worth asking about (compared 13 filings on Oct 24, 2026)

Note · Dec 20, 2011 – Oct 8, 2021

Jay Lichter, Ph.D. appears on 2 deals that stopped filing before reaching their target

Nerio Therapeutics, Inc. (last filing Oct 8, 2021; $3,500,003 sold of $10,000,005); ReVision Therapeutics, Inc. (last filing Dec 20, 2011; $2,308,332 sold of $5,000,000). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Nerio Therapeutics, Inc. — PartnerFacts page ↗ReVision Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jun 13, 2025 – Jul 1, 2025

Form D filed 18 days after the first sale — Arialys Therapeutics, Inc.

The filing says the first sale was Jun 13, 2025. The Form D was filed Jul 1, 2025 — 18 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 3 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Jul 1, 2025 ↗Arialys Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Aug 21, 2021 – Oct 8, 2021

Form D filed 48 days after the first sale — Nerio Therapeutics, Inc.

The filing says the first sale was Aug 21, 2021. The Form D was filed Oct 8, 2021 — 48 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 33 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Oct 8, 2021 ↗Nerio Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Apr 8, 2010 – Jul 1, 2025

8 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Arialys Therapeutics, Inc. (latest filing Jul 1, 2025) · No amendment in the last 12 months on an offering that may still be open — Arialys Therapeutics, Inc. (latest filing Dec 2, 2022) · No amendment in the last 12 months on an offering that may still be open — Nerio Therapeutics, Inc. (latest filing Oct 8, 2021) · No amendment in the last 12 months on an offering that may still be open — Janux Therapeutics, Inc. (latest filing Jul 14, 2020) · No amendment in the last 12 months on an offering that may still be open — Nerio Therapeutics, Inc. (latest filing Jul 13, 2020) · and 3 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Jul 1, 2025 ↗Arialys Therapeutics, Inc. — PartnerFacts page ↗Form D · Dec 2, 2022 ↗Form D · Oct 8, 2021 ↗
Sources
Worth asking · Sep 3, 2010 – Jun 2, 2011

Jay Lichter, Ph.D. is no longer listed on the Jun 2, 2011 amendment — Otonomy, Inc.

Jay Lichter, Ph.D. appears on the Sep 3, 2010 Form D (executive officer, director) but not on the Jun 2, 2011 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D · Sep 3, 2010 ↗Form D/A · Jun 2, 2011 ↗Jay Lichter, Ph.D. — PartnerFacts page ↗Otonomy, Inc. — PartnerFacts page ↗
Sources
Note · Dec 2, 2022 – Jul 1, 2025

Jay Lichter, Ph.D.'s role changed at Arialys Therapeutics, Inc.: executive officer, director → director

The Dec 2, 2022 filing lists Jay Lichter, Ph.D. as executive officer, director; the Jul 1, 2025 Form D lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Dec 2, 2022 ↗Form D · Jul 1, 2025 ↗Jay Lichter, Ph.D. — PartnerFacts page ↗Arialys Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Sep 3, 2010 – Jun 2, 2011

Offering amount changed between filings — Otonomy, Inc.

The Sep 3, 2010 filing says $38,644,354 offered; the Jun 2, 2011 Form D/A says $38,844,352.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Sep 3, 2010 ↗Form D/A (later) · Jun 2, 2011 ↗Otonomy, Inc. — PartnerFacts page ↗
Sources
Note · Apr 23, 2010 – Dec 20, 2011

Address moved from San Diego, CA to La Jolla, CA — ReVision Therapeutics, Inc.

The people listed on the Apr 23, 2010 filing give San Diego, CA; on the Dec 20, 2011 filing they give La Jolla, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Apr 23, 2010 ↗Form D · Dec 20, 2011 ↗ReVision Therapeutics, Inc. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

None reported on 13 offerings — no sales commissions, finder's fees or proceeds to insiders

Per-offering detail
Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jul 1, 2025 D
Arialys Therapeutics, Inc.
File 021-550394
$0$0$0None listed on this filingEDGAR ↗
Dec 2, 2022 D
Arialys Therapeutics, Inc.
File 021-466443
$0$0$0None listed on this filingEDGAR ↗
Oct 8, 2021 D
Nerio Therapeutics, Inc.
File 021-416368
$0$0$0None listed on this filingEDGAR ↗
Apr 30, 2021 D
Janux Therapeutics, Inc.
File 021-397786
$0$0$0None listed on this filingEDGAR ↗
Mar 12, 2021 D
Janux Therapeutics, Inc.
File 021-392167
$0$0$0None listed on this filingEDGAR ↗
Jul 14, 2020 D
Janux Therapeutics, Inc.
File 021-370889
$0$0$0None listed on this filingEDGAR ↗
Jul 13, 2020 D
Nerio Therapeutics, Inc.
File 021-370830
$0$0$0None listed on this filingEDGAR ↗
Oct 23, 2013 D
ARATANA THERAPEUTICS, INC.
File 021-205105
$0$0$0None listed on this filingEDGAR ↗
Dec 20, 2011 D
ReVision Therapeutics, Inc.
File 021-170338
$0$0$0None listed on this filingEDGAR ↗
Sep 3, 2010 D
Otonomy, Inc.
File 021-147275
$0$0$0None listed on this filingEDGAR ↗
Jun 9, 2010 D
Otonomy, Inc.
File 021-143212
$0$0$0None listed on this filingEDGAR ↗
Apr 23, 2010 D
ReVision Therapeutics, Inc.
File 021-141014
$0$0$0None listed on this filingEDGAR ↗
Apr 23, 2010 D
ReVision Therapeutics, Inc.
File 021-141016
$0$0$0None listed on this filingEDGAR ↗

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 6

Every issuer that named Jay Lichter, Ph.D. on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

AT
Biotechnology

Arialys Therapeutics, Inc.

La Jolla, CA · Dec 2, 2022 → Jul 1, 2025 · 2 filings
  • Jul 1, 2025 · D · $14,800,017 sold of $24,800,006 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 2, 2022 · D · $14,333,337 sold of $55,000,000 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $14.8M from 7 investors (60% of the $24.8M target) as of the latest filing. Jay is listed as director, executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

NT
Biotechnology · group: Avalon

Nerio Therapeutics, Inc.

La Jolla, CA · Jul 13, 2020 → Oct 8, 2021 · 2 filings
  • Oct 8, 2021 · D · $3,500,003 sold of $10,000,005 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 13, 2020 · D · $3,002,850 sold of $5,752,853 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3.5M from 5 investors (35% of the $10M target) as of the latest filing. Jay is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

JT
Biotechnology · group: Avalon

Janux Therapeutics, Inc.

La Jolla, CA · Jul 14, 2020 → Apr 30, 2021 · 3 filings
  • Apr 30, 2021 · D · $125,000,073 sold of $125,000,073 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 12, 2021 · D · $56,000,030 sold of $56,000,030 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 14, 2020 · D · $11,439,224 sold of $15,939,220 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $125M from 22 investors (100% of the $125M target) as of the latest filing. Jay is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Pharmaceuticals

ARATANA THERAPEUTICS, INC.

Kansas City, KS · Oct 23, 2013
  • Oct 23, 2013 · D · $29,750,000 sold of $29,750,000 · 17 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $29.8M from 17 investors (100% of the $29.8M target) as of the latest filing. Jay is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RT
Biotechnology

ReVision Therapeutics, Inc.

La Jolla, CA · Apr 23, 2010 → Dec 20, 2011 · 3 filings
  • Dec 20, 2011 · D · $500,000 sold of $5,000,000 · 2 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Apr 23, 2010 · D · $2,308,332 sold of $4,999,972 · 11 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Apr 23, 2010 · D · $562,039 sold of $562,039 · 23 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $2.31M from 23 investors (46% of the $5M target) as of the latest filing. Jay is listed as executive officer, director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

O
Biotechnology · group: Zacharon

Otonomy, Inc.

San Diego, CA · Jun 9, 2010 → Sep 3, 2010 · 2 filings
  • Sep 3, 2010 · D · $10,037,465 sold of $38,644,354 · 10 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jun 9, 2010 · D · $10,567,046 sold of $26,000,000 · 3 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $24.2M from 13 investors (63% of the $38.6M target) as of the latest filing. Jay is listed as executive officer, director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (1)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

People around Jay 33

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET.

TR
No photo found yet (own website and image search run after this page is viewed)
Person

Tighe Reardon

Executive Officer, Director · 6 shared filings (3 issuers) · also on 10 other issuers

Tighe Reardon is on 13 issuers in total — a repeat sponsor. Their page lists every one.

DD
No photo found yet (own website and image search run after this page is viewed)
Person

Douglas Downs

Executive Officer · 5 shared filings (2 issuers) · also on 10 other issuers

Douglas Downs is on 12 issuers in total — a repeat sponsor. Their page lists every one.

SH
No photo found yet (own website and image search run after this page is viewed)
Person

Stefan Heller

Director · 5 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

NM
No photo found yet (own website and image search run after this page is viewed)
Person

Nathan Mata

Executive Officer · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

DD
No photo found yet (own website and image search run after this page is viewed)
Person

David Campbell, Ph.D.

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

KK
No photo found yet (own website and image search run after this page is viewed)
Person

Kevin Kinsella

Director · 3 shared filings (1 issuer) · also on 6 other issuers

Kevin Kinsella is on 7 issuers in total — a repeat sponsor. Their page lists every one.

SD
No photo found yet (own website and image search run after this page is viewed)
Person

Sanford J. Madigan, Ph.D.

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

EH
No photo found yet (own website and image search run after this page is viewed)
Person

Ed Hurwitz

Director · 2 shared filings (1 issuer) · also on 5 other issuers

Ed Hurwitz is on 6 issuers in total — a repeat sponsor. Their page lists every one.

CT
No photo found yet (own website and image search run after this page is viewed)
Person

Court Turner

Director, Executive Officer · 2 shared filings (1 issuer) · also on 7 other issuers

Court Turner is on 8 issuers in total — a repeat sponsor. Their page lists every one.

JD
No photo found yet (own website and image search run after this page is viewed)
Person

Jeffrey Harris, M.D., Ph.D.

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

PD
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Thompson, M.D.

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

JD
No photo found yet (own website and image search run after this page is viewed)
Person

Jake Simson, Ph.D.

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

BH
No photo found yet (own website and image search run after this page is viewed)
Person

Brian Slingsby, M.D., Ph.D., M.P.H.

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

PB
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Bisgaard

Director · 1 shared filing (1 issuer) · also on 14 other issuers

Peter Bisgaard is on 15 issuers in total — a repeat sponsor. Their page lists every one.

BD
No photo found yet (own website and image search run after this page is viewed)
Person

Brian H. Dovey

Director · 1 shared filing (1 issuer) · also on 14 other issuers

Brian H. Dovey is on 15 issuers in total — a repeat sponsor. Their page lists every one.

CT
No photo found yet (own website and image search run after this page is viewed)
Person

Craig Tooman

Director · 1 shared filing (1 issuer) · also on 2 other issuers

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

HP
No photo found yet (own website and image search run after this page is viewed)
Person

Heather Preston

Director · 1 shared filing (1 issuer) · also on 4 other issuers

Heather Preston is on 5 issuers in total — a repeat sponsor. Their page lists every one.

CD
No photo found yet (own website and image search run after this page is viewed)
Person

Carl LeBel, Ph.D.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

PC
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Cayer

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

DW
No photo found yet (own website and image search run after this page is viewed)
Person

David Weber

Director · 1 shared filing (1 issuer) · also on 7 other issuers

David Weber is on 8 issuers in total — a repeat sponsor. Their page lists every one.

RG
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Gerber

Director · 1 shared filing (1 issuer) · also on 6 other issuers

Robert Gerber is on 7 issuers in total — a repeat sponsor. Their page lists every one.

SG
No photo found yet (own website and image search run after this page is viewed)
Person

Sheila Gujrathi

Director · 1 shared filing (1 issuer) · also on 5 other issuers

Sheila Gujrathi is on 6 issuers in total — a repeat sponsor. Their page lists every one.

LM
No photo found yet (own website and image search run after this page is viewed)
Person

Louise A. Mawhinney

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

ED
No photo found yet (own website and image search run after this page is viewed)
Person

Ernst Heinen, D.V.M., Ph.D.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

SD
No photo found yet (own website and image search run after this page is viewed)
Person

Steven St. Peter, M.D.

Executive Officer, Director · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

LD
No photo found yet (own website and image search run after this page is viewed)
Person

Linda Rhodes, V.M.D., Ph.D.

Executive Officer, Director · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

RD
No photo found yet (own website and image search run after this page is viewed)
Person

Ronald L. Meeusen, Ph.D.

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Julia Stephanus

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

John P. McKearn

Director · 1 shared filing (1 issuer) · also on 16 other issuers

John P. McKearn is on 17 issuers in total — a repeat sponsor. Their page lists every one.

VC
No photo found yet (own website and image search run after this page is viewed)
Person

Vickie L. Capps

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

PD
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Flynn, Ph.D.

Executive Officer, Director · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

AD
No photo found yet (own website and image search run after this page is viewed)
Person

Ashish Xavier, Ph.D.

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

JV
No photo found yet (own website and image search run after this page is viewed)
Person

John Vander Vort

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jay Lichter, Ph.D.. Their page shows their other deals.

The team behind the deals

A
Sponsor group

Avalon

15 issuers · 31 filings · $705.3M reported sold · 2010–2025

One team, 15 deal companies. Jay Lichter, Ph.D. is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Jay Lichter, Ph.D..

Z
Sponsor group

Zacharon

2 issuers · 6 filings · $24.2M reported sold · 2010–2012

One team, 2 deal companies. Jay Lichter, Ph.D. is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Jay Lichter, Ph.D..

Same business address

15 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); KY (Kentucky Secretary of State — Business Entity Search (sosbes.sos.ky.gov), searched by issuer name, data as of Oct 24, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

None of the 6 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Jay Lichter, Ph.D. by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 6 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Jay Lichter, Ph.D. is listed on: none on file. No website or social profile named in ARATANA THERAPEUTICS, INC.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #324,890 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Kansas City, KS). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗Kansas state courts — find the court ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗Kansas Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Jay Lichter, Ph.D. appears on a new Form D, or when a court case or SEC action is matched to them. See plans →